Results

Total Results: 801 records

Showing results for "described".

121. Recommendation: Chronic Obstructive Pulmonary Disease: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/chronic-obstructive-pulmonary-disease-screening
     May 10, 2022 - harms of bronchodilators and ICS in the treatment of COPD, such as heart failure and pneumonia, as described … Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described

122. Individualizing Cancer Screening in Older Adults | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/individualizing-cancer-screening-older-adults
     March 01, 2021 - The risks of false-positive screening results have been well described elsewhere 17  and range from emotional … However, these risks have rarely been specifically described for older adults, so we can only speculate

123. The U.S. Preventive Services Task Force: An Evidence-Based Prevention Resource for Nurse Practitioners | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/evidence-based-prevention-resource-nurse-practitioners
     April 01, 2019 - These processes are fully described in a procedure manual and in a series of articles available on the … As described above, quality-of-care indicators document very well the gaps between recommended preventive

124. Evidence Summary: Oral Health in Children and Adolescents Aged 5 to 17 Years: Screening and Preventive Interventions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/oral-health-children-adolescents-screening-preventive-interventions
     November 07, 2023 - results from 2 fair-quality trials of xylitol; 15 , 16 results of 8 poor-quality xylitol trials are described … on study limitations, consistency, precision, reporting bias, and applicability, using the approach described … All adverse events were described as self-limited, although 4 children were withdrawn due to mild adverse … The harms of preventive interventions were sparsely reported, although serious harms were not described

125. Archived: Evidence Summary: Genital Herpes Infection: Serologic Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/genital-herpes-screening-november-2016
     December 20, 2016 - Two included studies described whether participants had current or prior symptoms consistent with genital … studies, the proportion of participants who had current or past symptoms of genital herpes was not described … and adolescent clinics. 25 Of the 1190 enrolled, 820 (68%) had serologic testing (type of test not described … daily suppressive antiviral medication with placebo also reported viral shedding outcomes and were described

126. 6Ngc3Byq9Jeby Pwyvd6Or (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/6Ngc3byQ9jeBy_pwyvD6or
     September 01, 2014 - Benefits of CEA or CAAS Beyond Medical Therapy We included 3 RCTs (Table 1) described in 12 pub- lications … (32–43) that compared CEA with medical ther- apy and 3 systematic reviews described in 5 publications … Trial Characteristics The RCTs that compared CEA with medical therapy have been described. … reflect the published literature, and most key issues limiting applica- bility of the evidence have been described

127. Update on the Methods of the U.S. Preventive Services Task Force: Insufficient Evidence (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/inevidup.pdf
     September 01, 2009 - a decision to transform what was formerly called an “I recommendation” into an “I statement,” as described … The 4 information groups came to be described as “domains,” a term that connotes hierar­ chical ranking

128. Archived: Final Research Plan: Drug Use, Illicit: Primary Care Interventions for Children and Adolescents | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan18/drug-use-illicit-primary-care-interventions-for-children-and-adolescents-march-2014
     May 15, 2013 - Revision [DSM-IV-TR]) or drug use disorder (DSM V); studies of children and adolescents narratively described

129. The Audit (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/23KAofmVPv2qeqPqxBqfXE
     The Audit The AUDIT PATIENT: Because alcohol use can affect your health and can interfere with certain medications and treatments, it is important that we ask some questions about your use of alcohol. Your answers will remain confidential, so please be honest. Place an X in one box that best describes your answe…

130. Recommendation: Hypertensive Disorders of Pregnancy: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertensive-disorders-pregnancy-screening
     September 19, 2023 - The study population in the large US trial (n = 2328) of a reduced prenatal visit schedule was described … White (81%) and Hispanic (12%) individuals. 1 , 38 , 41 One-third of study participants (32%) were described … Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described

131. Archived: Evidence Summary: Preeclampsia: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/preeclampsia-screening-april-2017
     April 25, 2017 - models we identified with good or better discrimination based on the c statistic (≥0.80) 30 are described … The risk assessment model used and the content of the counseling were not well described, and the results … descriptive information about the model available in Wright et al. 66 b Clinical history algorithm described … Multivariable risk prediction 1 (prospective cohort) n = 2550 Fair Risk prediction model not clearly described … ; intensive counseling and changes to clinical care based on risk not clearly described; unable to isolate

132. JAMA JATS (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/pKa4_DYwzuyD6RDgYzLMbo
     August 22, 2018 - - der abuse and abuse of vulnerable adults, this literature is not or- ganized by KQ but is briefly described … accuracy of a tool designed to detect past-year or current overall IPV (not subtypes of abuse only) are described … , provision of an IPV resource sheet) in control groups varied across studies and sometimes was not described … e Usual care described as 2 violence screening questions on clinic intake form and usual clinic protocol … f Usual care described as standard IPV question on intake sheet and referral if IPV was discussed.

133. untitled (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/VNs-WaxpPcsodxCb57gYmn
     January 03, 2017 - The USPSTF reviewed evidence from 76 good- to fair-quality treatment trials that described the effect … In response to comments, the USPSTF described com- mon symptoms of OSA and defined what is meant by persons … Authors followed the policy regarding conflicts of interest described at https://www .uspreventiveservicestaskforce.org

134. Procedure Manual Section 6. Methods for Arriving at a Recommendation | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-section-6-methods-arriving-recommendation
     July 06, 2017 - Analytic Framework 6.8 Assessing Magnitude of Net Benefit 6.1 Overview The preceding sections have described … link between intermediate and health outcomes is similar to the process for other key questions, as described … questions ( Table 2 ), the coherence across all the evidence for the linkage, and other considerations, as described

135. Screening for Prostate Cancer: Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/zxXWqacXvfKPyQB9LCrZjX
     August 01, 2008 - Unfortu- nately, the previously described gaps in the evidence re- garding potential benefits of screening … However, the natural history of PSA-detected, non- palpable, localized prostate cancer is poorly described

136. Archived: Evidence Summary: Visual Impairment in Children Ages 1-5: Screening, 2004 | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/visual-impairment-in-children-ages-1-5-screening-2004
     May 13, 2004 - specificity of preschool screening tools, and 3 compared treatment interventions for preschool amblyopia (RCT described … Quality ratings for the studies described in this update of the evidence are in Table 3 .

137. Evaluating Primary Care Behavioral Counseling Interventions: An Evidence-based Approach (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/behavintr.pdf
     January 01, 2010 - necessarily varies from behavior to behavior, but clinical intervention targeting any behavior change can be described … change, whether the behavior is being added or deleted, and by factors individual to the patient, as described

138. Procedure Manual Section 5. Modeling | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-section-5-modeling
     July 05, 2017 - considered indirect evidence, it is sufficient basis for using modeling, subject to the considerations described

139. Ocular Prophylaxis of Gonococcal Ophthalmia Neonatorum: Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/nfq4s8fZc4JZeprE8FnQYW
     August 01, 2010 - The methodology of the literature search is described in Appendix 1.

140. Archived: Final Research Plan: High Blood Pressure in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan6/high-blood-pressure-in-adults-screening-monitoring-october-2015
     September 15, 2013 - The figure is an analytic framework that depicts the five Key Questions described in the Research Plan